[go: up one dir, main page]

WO1993018055B1 - Peptide stimulant la reponse des lymphocytes cytotoxiques a la gp160 du vih-1 - Google Patents

Peptide stimulant la reponse des lymphocytes cytotoxiques a la gp160 du vih-1

Info

Publication number
WO1993018055B1
WO1993018055B1 PCT/US1993/001925 US9301925W WO9318055B1 WO 1993018055 B1 WO1993018055 B1 WO 1993018055B1 US 9301925 W US9301925 W US 9301925W WO 9318055 B1 WO9318055 B1 WO 9318055B1
Authority
WO
WIPO (PCT)
Prior art keywords
hiv
acid sequence
amino acid
respone
peptides
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US1993/001925
Other languages
English (en)
Other versions
WO1993018055A3 (fr
WO1993018055A2 (fr
Filing date
Publication date
Priority claimed from US07/847,311 external-priority patent/US5976541A/en
Application filed filed Critical
Priority to EP93907180A priority Critical patent/EP0630385A1/fr
Priority to AU37878/93A priority patent/AU668927B2/en
Priority to CA002131153A priority patent/CA2131153C/fr
Publication of WO1993018055A2 publication Critical patent/WO1993018055A2/fr
Publication of WO1993018055A3 publication Critical patent/WO1993018055A3/fr
Publication of WO1993018055B1 publication Critical patent/WO1993018055B1/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Abstract

L'invention se rapporte à des peptides possédant une activité élevée dans le déclenchement d'une réponse de lymphocytes T cytotoxiques par rapport à la glycoprotéine gp160 de l'enveloppe du VIH-1. L'invention se rapporte également à l'activation des peptides des restes 12 à 15 par dégradation protéolytique en peptides plus courts, ainsi qu'à des techniques générales destinées à caractériser ces procédés d'activation.
PCT/US1993/001925 1992-03-06 1993-03-08 Peptide stimulant la reponse des lymphocytes cytotoxiques a la gp160 du vih-1 Ceased WO1993018055A2 (fr)

Priority Applications (3)

Application Number Priority Date Filing Date Title
EP93907180A EP0630385A1 (fr) 1992-03-06 1993-03-08 Peptide puissant pour la stimulation des lymphocytes t cytotoxiques specifiques de l'enveloppe du vih-1
AU37878/93A AU668927B2 (en) 1992-03-06 1993-03-08 Peptides stimulating cytotoxic lymphocytes response to HIV-I GP 160
CA002131153A CA2131153C (fr) 1992-03-06 1993-03-08 Peptides stimulant la reponse cytotoxique des lymphocytes a la gp 160 du virus vih-1

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US07/847,311 US5976541A (en) 1988-01-26 1992-03-06 Potent peptide for stimulation of cytotoxic T lymphocytes specific for the HIV-1 envelope
US847,311 1992-03-06

Publications (3)

Publication Number Publication Date
WO1993018055A2 WO1993018055A2 (fr) 1993-09-16
WO1993018055A3 WO1993018055A3 (fr) 1994-03-17
WO1993018055B1 true WO1993018055B1 (fr) 1994-06-09

Family

ID=25300315

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1993/001925 Ceased WO1993018055A2 (fr) 1992-03-06 1993-03-08 Peptide stimulant la reponse des lymphocytes cytotoxiques a la gp160 du vih-1

Country Status (5)

Country Link
US (1) US5976541A (fr)
EP (1) EP0630385A1 (fr)
AU (1) AU668927B2 (fr)
CA (1) CA2131153C (fr)
WO (1) WO1993018055A2 (fr)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5128319A (en) 1987-08-28 1992-07-07 Board Of Regents, The University Of Texas System Prophylaxis and therapy of acquired immunodeficiency syndrome
US6210873B1 (en) 1987-08-28 2001-04-03 Board Of Regents, The University Of Texas System Methods and compositions for the priming of specific cytotoxic T-lymphocyte response
AU6363094A (en) * 1993-03-15 1994-10-11 Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services, The Peptide coated dendritic cells as immunogens
US5603933A (en) * 1993-08-31 1997-02-18 Board Of Regents, The University Of Texas CD4 peptides for binding to viral envelope proteins
NL9400384A (nl) * 1994-03-11 1995-10-02 Smit Victor Retrovirus-vaccins, vaccinatie en immunotherapie tegen retrovirale infecties.
GB9426153D0 (en) * 1994-12-23 1995-02-22 Medical Res Council Improvements in or relating to vaccines
US6395714B1 (en) * 1999-02-24 2002-05-28 Aventis Pasteur Limited Expressing gp140 fragment of primary HIV-1 isolate
CN1635876A (zh) 2000-02-04 2005-07-06 杜克大学 人免疫缺陷病毒疫苗
WO2001072331A1 (fr) * 2000-03-31 2001-10-04 Vaccine Chip Technology Aps Proprietes immunostimulantes d'un fragment de tgf-beta
WO2003037264A2 (fr) * 2001-10-29 2003-05-08 Genzyme Corporation Composes therapeutiques anti-vih (vpr)
US20030162720A1 (en) * 2001-10-29 2003-08-28 Nicolette Charles A. Therapeutic anti-HIV (IV9) compounds
WO2005111065A2 (fr) * 2004-04-30 2005-11-24 The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Activation d'un epitope du vih cd4 humain
EP2620446A1 (fr) 2012-01-27 2013-07-31 Laboratorios Del Dr. Esteve, S.A. Immunogènes pour la vaccination contre le VIH
CA3161633A1 (fr) 2019-11-14 2021-05-20 Aelix Therapeutics, S.L. Regimes posologiques pour vaccins

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0387915B1 (fr) * 1984-10-18 1993-03-10 Institut Pasteur Antigènes F du virus humain d'immunodéficience, et leurs applications
JPS63501716A (ja) * 1985-10-24 1988-07-14 サウスウエスト・ファウンデ−ション・フォア・バイオメディカル・リサ−チ 合成ペプチドおよびａｉｄｓおよびａｒｃの診断ならびにワクチン注射へのその使用
AU617088B2 (en) * 1986-06-12 1991-11-21 Biogen, Inc. Peptides involved in the pathogenesis of hiv infection
WO1988005051A1 (fr) * 1986-12-30 1988-07-14 United States Of America, Represented By The Unite Peptides synthetiques induisant une immunite cellulaire au virus du sida et aux proteines virales du sida
US5019387A (en) * 1987-09-08 1991-05-28 Duke University Production of antibodies to HIV
US5013548A (en) * 1987-09-08 1991-05-07 Duke University Production of antibodies to HIV
US5820865A (en) * 1988-01-26 1998-10-13 The United States Of America As Represented By The Department Of Health And Human Services Method to induce cytotoxic T Lymphocytes specific for a broad array of HIV-1 isolates using hybrid synthetic peptides
JP2569185B2 (ja) * 1988-01-26 1997-01-08 アメリカ合衆国 抗ｈｉｖ応答を喚起する合成抗原
US5562905A (en) * 1988-04-26 1996-10-08 E. I. Du Pont De Nemours And Company Human immunodeficiency virus (hiv) env-coded peptide capable of eliciting hiv-inhibiting antibodies in mammals
IL94558A0 (en) * 1989-06-06 1991-03-10 Merck & Co Inc Conjugate immunogen for aids and vaccine and pharmaceutical compositions containing it
FR2650954B1 (fr) * 1989-08-18 1992-02-28 Pasteur Institut Composition resultant de la reunion d'un epitope b de la glycoproteine d'enveloppe d'un retrovirus du type iv et d'un epitope t issu d'une proteine distincte codee par ce retrovirus et leur application a la production d'anticorps protecteurs contre le sida
US5254682A (en) * 1989-12-08 1993-10-19 Merck & Co., Inc. Cyclic renin inhibitors containing 3(S)-amino-4-cyclohexyl-2(R)-hydroxy-butanoic acid or 4-cyclo-hexyl-(2R, 3S)-dihydroxybutanoic acid or related analogs
JPH03271233A (ja) * 1990-03-19 1991-12-03 Inst Pasteur ウイルスエンベロープ糖タンパク質及びその糖タンパク質の中和エピトープに対応するペプチドの間の相乗作用による、ウイルス性感染に対する防御の誘発
CA2056911C (fr) * 1990-12-11 1998-09-22 Yuuichi Nagano Inhibiteurs de la protease de vih

Similar Documents

Publication Publication Date Title
WO1993018055B1 (fr) Peptide stimulant la reponse des lymphocytes cytotoxiques a la gp160 du vih-1
EP1714974A3 (fr) Procédés et compositions pour empêcher certains phénomènes associés avec la fusion avec la membrane, en particulier la transmission du VIH
CA2140663A1 (fr) Composes inhibant la replication du vih
NZ267803A (en) Synthetic peptides which inhibit hiv transmission and other viral diseases
WO1996040915A3 (fr) Nouveaux ligands de ctla4/cd28 et leurs utilisations
AU3762889A (en) Hiv-3 retrovirus and its use
EP0339504A3 (fr) Virus d'immunodéficience humaine (HIV) peptide env-codé capable de provoquer les anticorps inhibiteurs du HIV dans les mammifères
CA2020668A1 (fr) Proteines fusionnees ou hybrides comprenant de la lymphokine et un antigene viral
WO1995001442A3 (fr) Sequences de nucleotides et sequences d'acides amines du gene d'enveloppe 1 de 51 isolats du virus de l'hepatite c et utilisation de reactifs derives desdites sequences en tant que reactifs de diagnostic et vaccins
AU2010088A (en) Synthetic lipid vesicle carriers
CA2193210A1 (fr) Procede d'induction de reaction immunitaire au moyen d'un virus vivant de l'encephalite equine de venezuela exprimant un immunogene heterologue
AU1353295A (en) Peptides derived from a retrovirus of the HIV group, and their use
EP0328403A3 (fr) Peptides synthétiques relatifs à la protéine HIV-GP120-env. et leur application
CA2358915A1 (fr) Polypeptides vih env modifies
WO1993018055A3 (fr) Peptide stimulant la reponse des lymphocytes cytotoxiques a la gp160 du vih-1
ES2010231A6 (es) Metodo para fabricar particulas de proteinas de fusion y metodo para expresar estas proteinas.
EP0272858A3 (fr) Protéines recombinantes d'enveloppe du HIV, produites dans des cellules d'insectes
ES2010230A6 (es) Metodo para fabricar particulas de proteinas de fusion con parte de su secuencia homologa a proteinas de hiv y metodo para expresar dichas proteinas.
WO2002077189A3 (fr) Cyanovirines resistant a la glycosylation et conjugues, compositions, acides nucleiques, vecteurs, cellules hotes, associes, et procedes d'obtention et d'utilisation des cyanovirines non glycosylees
HUT76102A (en) Peptides that elicit neutralizing antibodies against genetically divergent hiv-1 strains
AU3629389A (en) Novel peptides suppressing the function of the immune system, pharmaceutical compositions containing them and process for preparing same
CA2084386A1 (fr) Antigene associe au vih
US5817315A (en) Recombinant vaccine
EP0327180A3 (fr) Vaccin contenant des polypeptides dérivés du gène de l'enveloppe du virus de l'immunodéficience humaine de type I
EP0232107A3 (fr) Dérivé du polypeptide de la lymphotoxine humaine